검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Etoposide, cytarabine, vincristine, dexamethasone (Etoposide, cytarabine, vincristine, dexamethasone) AbbVie·Acute Lymphoblastic Leukemia ORR 100% |
|---|---|
Overview Program | Etoposide, cytarabine, vincristine, dexamethasone |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker-evaluable patients, responses to venetoclax plus VXL-based or cytarabine-based chemotherapy were ob |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Behind the bleeding: rare and relentless uterine lymphoma ending in chemotherapy toxicity.. A woman in her 30s presented with irregular vaginal bleeding and abdominal distension. Initial imaging suggested a uterine fibroid; however, intraoperative findings during planned laparotomy were atypical, prompting an excisional biopsy. The initial pathological diagnosis was endometrial stromal sarcoma, an… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical PFS | 91 |
Clinical OS | 91 |
Clinical Result source | ClinicalTrials.gov NCT00450801 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Etoposide, cytarabine, vincristine, dexamethasone (Etoposide, cytarabine, vincristine, dexamethasone) AbbVie·Acute Lymphoblastic Leukemia ORR 100% |
|---|---|
Overview Program | Etoposide, cytarabine, vincristine, dexamethasone |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker-evaluable patients, responses to venetoclax plus VXL-based or cytarabine-based chemotherapy were ob |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Behind the bleeding: rare and relentless uterine lymphoma ending in chemotherapy toxicity.. A woman in her 30s presented with irregular vaginal bleeding and abdominal distension. Initial imaging suggested a uterine fibroid; however, intraoperative findings during planned laparotomy were atypical, prompting an excisional biopsy. The initial pathological diagnosis was endometrial stromal sarcoma, an… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical PFS | 91 |
Clinical OS | 91 |
Clinical Result source | ClinicalTrials.gov NCT00450801 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교